Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Clearmind Medicine Inc.
CMND · SEC Filings
website
4
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the deve...
Price
5.5
Market Cap
2.79 M
Float
507.23 K
Country
CA
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about CMND
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Clearmind Medicine Inc.
CMND · SEC Filings
507.23 K
Float
5.5
Price
2.79 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
20-F
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Jan 20, 2026
20-F
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Jan 22, 2025
20-F/A
Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
Mar 27, 2024
20-F/A
Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
Mar 18, 2024
20-F
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Jan 29, 2024
20-F
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Feb 3, 2023
News
TYPE
HEADLINE
FILED AT
6-K
Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
Oct 27, 2026
6-K
Clearmind Medicine Announces $2 Million Promissory Note Financing
Oct 16, 2026
6-K
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
Oct 13, 2026
6-K
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
Oct 8, 2026
6-K
Clearmind Medicine Submits Recommendations to FDA Regarding Psychedelic Therapies and Non-Hallucinogenic Neuroplastogens
Oct 7, 2026
6-K
Clearmind Medicine Inc. Announces 1-for-8 Reverse Share Split
Sep 30, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B5
SHELF OFFERING | Shares amount: 16,000,000 | Share price: $0.10 | Offering amount: $1,600,000 | Amount sold to date: $5,650,000
Dec 3, 2025
424B5
REGISTERED OFFERING
Nov 26, 2025
424B5
REGISTERED OFFERING
Nov 19, 2025
424B5
REGISTERED OFFERING
Nov 17, 2025
424B5
REGISTERED OFFERING
Nov 13, 2025
424B3
UPDATED
Jun 28, 2024
Registrations
TYPE
HEADLINE
FILED AT
POS AM
SHARE RESALE REGISTRATION | Shares: 21,875
Jun 15, 2026
F-3
SHARE RESALE REGISTRATION
Apr 30, 2026
POS AM
Form POS AM - Post-Effective amendments for registration statement
Mar 25, 2026
POS AM
Form POS AM - Post-Effective amendments for registration statement
Mar 25, 2026
F-3
SHARE RESALE REGISTRATION
Feb 17, 2026
POS AM
Form POS AM - Post-Effective amendments for registration statement
Jan 27, 2026
Proxies
TYPE
HEADLINE
FILED AT
Ownerships
TYPE
HEADLINE
FILED AT
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
Jun 22, 2026
EFFECT
Form EFFECT - Notice of Effectiveness
May 8, 2026
CORRESP
Form CORRESP - Correspondence
May 6, 2026
LETTER
Form UPLOAD - SEC-generated letter
May 6, 2026
EFFECT
Form EFFECT - Notice of Effectiveness
Mar 31, 2026
EFFECT
Form EFFECT - Notice of Effectiveness
Mar 31, 2026
